KYSE-520 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

The KYSE-520 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC) provides a robust, validated subcutaneous tumor platform for preclinical evaluation of radiation sensitivity, chemotherapy response, and novel targeted agents in moderately differentiated ESCC. At Alfa Cytology, we deliver fully customizable KYSE-520 xenograft studies with rigorous quality control, real-time tumor monitoring, and comprehensive endpoint analysis to accelerate your preclinical pipeline from compound screening to IND-enabling data packages.

Overview of KYSE-520 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

The KYSE-520 cell line was established from a moderately differentiated primary esophageal squamous cell carcinoma (ESCC) in a 58-year-old female patient of Japanese descent. As a member of the well-characterized KYSE series, this cell line exhibits epithelial-like morphology with adherent monolayer growth and retains key molecular features of ESCC, including TP53 splice acceptor mutations and MYC oncogene involvement. KYSE-520 cells demonstrate heterogeneity comprising both epithelial-like (CD44v+) and mesenchymal-like (CD44v-) subpopulations capable of interconversion, reflecting dynamic epithelial-mesenchymal plasticity (EMP) that closely mirrors cancer stem cell traits and chemoresistance mechanisms observed in clinical ESCC tumors.

In xenograft applications, KYSE-520 forms moderately differentiated subcutaneous tumors that faithfully recapitulate the histopathological architecture of human ESCC, including keratin pearl formation and invasive growth patterns. The model has been extensively validated for radiation and chemotherapy response studies, making it an essential tool for preclinical assessment of novel therapeutic strategies including EGFR-targeted agents, immune checkpoint inhibitors, and combination regimens. Its well-defined doubling time and consistent engraftment rate in immunocompromised mice provide a reliable platform for longitudinal tumor growth monitoring and pharmacodynamic endpoint evaluation.

Figure 1. Selenium prevents cell proliferation and colony formation in ESCC cell lines. (Ahsan, Anil, et al., 2022)

Cell Line Information: KYSE-520

The following table summarizes the comprehensive characteristics of the KYSE-520 cell line, providing essential reference data for experimental design and protocol optimization in xenograft studies.

Our Services

Alfa Cytology offers end-to-end KYSE-520 xenograft model services tailored to your preclinical objectives, from initial cell line authentication and in vitro potency confirmation to in vivo tumor establishment, treatment administration, and multi-parameter endpoint analysis. Our experienced team ensures every study is conducted under standardized protocols with detailed documentation, enabling seamless integration into your regulatory submission and publication workflows.

Workflow of KYSE-520 Xenograft Model Construction

The construction of the KYSE-520 xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth, minimal animal distress, and reliable pharmacological readouts. Each stage incorporates stringent validation checkpoints to maintain model integrity throughout the study duration.

1. Step 1: Cell Line Authentication and Quality Control: KYSE-520 cells are authenticated via STR profiling and confirmed mycoplasma-negative before expansion. Cells are cultured in RPMI 1640 with 10% FBS, harvested at 70-80% confluence, and viability is assessed by trypan blue exclusion (>=95% viability required).
2. Step 2: Cell Preparation and Matrigel Suspension: Harvested cells are washed twice in sterile PBS, counted, and resuspended at a concentration of 1x10^7 cells/mL in a 1:1 mixture of serum-free RPMI 1640 and high-concentration Matrigel. The suspension is kept on ice to prevent premature gelation.
3. Step 3: Subcutaneous Implantation: Immunocompromised mice (NOD/SCID or BALB/c nude, 6-8 weeks old) are anesthetized, and 100 microL of the cell-Matrigel suspension (1x10^6 cells per injection) is implanted subcutaneously into the right flank using a 25-gauge needle. Tumor formation is monitored by palpation beginning on Day 7.
4. Step 4: Tumor Monitoring and Randomization: Tumor volumes are measured twice weekly using digital calipers (V = 0.5 x length x width^2). Once tumors reach 100-150 mm^3, mice are randomized into treatment and control groups (n=8-10 per group) based on tumor volume and body weight stratification.
5. Step 5: Treatment Administration and In-Life Monitoring: Test compounds are administered according to the study design (PO, IP, IV, or intratumoral). Animals are monitored daily for body weight, clinical signs, and tumor burden. Dose adjustments are documented with veterinary oversight.
6. Step 6: Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and photographed. Tissue samples are fixed in 10% neutral buffered formalin for histopathology (H&E, IHC), snap-frozen in liquid nitrogen for molecular analysis, or dissociated for flow cytometry. Serum and plasma are collected for pharmacokinetic profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the KYSE-520 Xenograft Model at Alfa Cytology.

Case Study-KYSE-520 Xenograft Model Development

In a representative preclinical engagement, the KYSE-520 xenograft model was successfully established with a tumor take rate exceeding 90% and consistent latency of 10-14 days post-implantation. Tumor-bearing mice demonstrated steady exponential growth with mean doubling times of approximately 5-7 days under vehicle control conditions. Treatment arms evaluating a candidate EGFR inhibitor showed dose-dependent tumor growth inhibition, with the high-dose cohort achieving statistically significant reduction in tumor volume compared to vehicle controls. Pharmacodynamic analysis of excised tumors revealed modulation of downstream signaling markers including p-EGFR, p-Akt, and Ki-67 proliferation index, supporting target engagement. These data demonstrate the utility of the KYSE-520 model for robust preclinical efficacy screening and biomarker validation in ESCC drug development programs. (Specific data available upon request for client-customized reporting.)

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver KYSE-520 xenograft studies that meet the highest standards of preclinical research. Our integrated service model ensures seamless execution from study design to final report.

• Validated Cell Line Repository -- All KYSE-520 cells are STR-authenticated, mycoplasma-negative, and passaged under low-density conditions to maintain genetic stability.
• Customizable Study Designs -- We tailor dosing schedules, route of administration, combination regimens, and endpoint panels to match your specific program requirements.
• Real-Time Tumor Monitoring -- Digital caliper measurements and optional non-invasive imaging (bioluminescence, MRI) provide longitudinal data without compromising study integrity.
• Comprehensive Endpoint Analysis -- Histopathology, immunohistochemistry, flow cytometry, Western blot, qPCR, and PK/PD profiling are available under one roof.
• Regulatory-Ready Documentation -- Detailed study reports, raw data packages, and GLP-compliant documentation support IND submissions and peer-reviewed publications.
• Dedicated Project Management -- Each study is assigned a PhD-level scientist as primary contact, ensuring technical depth and rapid response to protocol modifications.

Contact Us

Ready to advance your ESCC therapeutic program with a validated KYSE-520 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our KYSE-520 Xenograft Model services.

For research use only. Not intended for any clinical use.